Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that the global Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating oral Avigan®/Reeqonus™ (favipiravir) as a potential at-home therapy for patients with mild-to-moderate COVID-19, which was being run by Appili Therapeutics, Inc. (“Appili”)(TSX: APLI), a consortium partner of AiPharma Global Holdings LLC (“AiPha